 |
3 Diseases |  |
216 Trials |
|
216 Trials |  |
891 News |  |
| 12345678910111213...1415» |
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Retrospective data, Journal, Combination therapy, Metastases: Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab. (Pubmed Central) - May 30, 2024
Additionally, the concurrent administration of pyrotinib and inetetamab could be an alternative to consider in the second and higher-line treatment for metastatic breast cancer. The adverse reactions of pyrotinib were tolerable in general.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study. (Pubmed Central) - May 29, 2024
The adverse reactions of pyrotinib were tolerable in general. The dual oral administration regimen (PyroC) has a promising ORR or PFS in HER2-positive mBC patients, with an acceptable safety profile and convenience.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors. (Pubmed Central) - May 16, 2024
Notably, pyrotinib plus trastuzumab was more effective than trastuzumab plus pertuzumab in inhibiting tumor growth and HER2 downstream pathways in HER2+ breast cancer with primary resistance to trastuzumab. These findings support clinical testing of the therapeutic efficacy of dual anti-HER2 treatment combining an intracellular small molecule with an extracellular antibody.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
P2 data, Clinical Trial,Phase II, Journal, IO biomarker, Metastases: Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial. (Pubmed Central) - May 13, 2024
This study demonstrates that pyrotinib plus albumin-bound paclitaxel as a first-line treatment regimen shows good efficacy and manageable safety for patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2-positive metastatic breast cancer. Besides, a significant association was identified between the expression levels of TLR3 and RET and the PFS in patients.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal, Real-world evidence, Real-world: Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study. (Pubmed Central) - May 11, 2024
Pyrotinib-based therapy is effective and tolerable in human epidermal growth factor receptor 2-positive metastatic breast cancer with BMs. Patients who underwent radiotherapy for BMs, particularly those who received pyrotinib concurrently with radiotherapy, exhibited a more favorable prognosis.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
P1 data, Journal, Metastases: Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer. (Pubmed Central) - Apr 30, 2024
P1/2
Responses were shown in patients with distinct HER2 aberrations. In summary, inetetamab in combination with pyrotinib demonstrated acceptable safety and antitumor activity among patients with advanced HER2-mutant NSCLC.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Real-world analysis of inetetamab combined with pyrotinib plus chemotherapy for the treatment of HER2-positive advanced breast cancer: A multi-center retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6770;
Inetetamab combined with pyrotinib plus albumin-bound paclitaxel might be the most effective combination therapies. All AEs were controllable and tolerable.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Clinical efficacy of pyrotinib combined with stereotactic radiosurgery in HER2-positive breast cancer brain metastases. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6763;
All AEs were controllable and tolerable. Our results suggest that pyrotinib combining with SRS is associated with promising efficacy and a satisfactory safety profile for Her2+ breast cancer brain metastases.
- GQ1001 / GeneQuantum Healthcare, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6484;
P1, P1/2
[1] HUANG L, et al. Cancer Research, 2023, 83(7_Supplement): 2702-.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6219;
Pyrotinib and trastuzumab synergistically achieve the comprehensive blockade of HER signaling pathway in HER2-dependent breast cancer. Patients with advanced HER2-positive breast cancer, who are addicted to HER2 signaling cascade, could be considered for pyrotinib in combination with trastuzumab and docetaxel as an alternative first line treatment.
- Cipterbin (inetetamab) / 3SBio
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6210;
The most frequently used treatment strategy was inetetamab plus pyrotinib-contained regimens (205/329, 62...0 months (first-line- vs. second-line combination therapy of inetetamab, pertuzumab and chemotherapy, p=0... Inetetamab-based combinations therapy demonstrated promising clinical activity and a manageable safety profile in patients with HER2-positive MBC, especially in the first-line setting.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6208;
P2
Inetetamab-based combinations therapy demonstrated promising clinical activity and a manageable safety profile in patients with HER2-positive MBC, especially in the first-line setting. Patients with radiotherapy-na
- Kadcyla (ado-trastuzumab emtansine) / Roche
T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6138;
However, multivariate analysis suggested that previous exposure of pertuzumab did not affect the PFS of T-DM1, and patients with HER2 2+ and lung metastasis may not be the advantageous population for T-DM1 treatment. Thrombocytopenia was a dose-limiting toxicity of T-DM1, and most patients could tolerate it well after dose adjustment.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6136;
P2
The study will proceed to the second stage. Clinical trial information: NCT05560308.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6128;
No increase treatment-related side effects was reported. Thus, the combination of pyrotinib and taxanes or vinorelbine regimen can be an option for HER2-positive MBC.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6124;
P2
Based on these findings, the study will continue to enroll up to 30 participants. Clinical trial information: NCT05806671.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
The relationship between PIK3CA mutations and survival in patients with human epidermal growth factor receptor 2 () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5203;
HER2-positive breast cancer patients with activated mutations in PIK3CA are less likely to benefit from pyrotinib combined with trastuzumab in the neoadjuvant setting, but this conclusion still needs to be confirmed by large-sample studies and long-term follow-up results. Clinical trial information: 1900022293.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5168;
P2
Clinical trial information: 1900022293. Our study showed pyrotinib didn
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5120;
P=N/A
Our study showed pyrotinib didn Background: Inetetamab, a novel monoclonal antibody targeting HER2, alters the Fc region amino acids, which induces ADCC stronger than trastuzumab...Eligible patients will be administered six cycles of neoadjuvant treatment, including carboplatin (AUC=6mg/mL
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5113;
7%, and even 72. 7% in HR+ patients.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5087;
In patients with HR-negative/HER2-positive EBC, a dual HER2-targeted combination of pyrotinib and trastuzumab, along with dalpiciclib in the absence of chemotherapy showed promising efficacy with encouraging pCR and ORR rates, as well as a favorable safety profile in the neoadjuvant setting. Clinical trial information: Chi-CTR-2200060748.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study. (Hall A; Poster Bd # 424) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3558;
P
Pyrotinib showed promising antitumor activity in recurrent/metastatic HER2-altered SGCs, and had a potential to prolong survival outcome as adjuvant treatment in LA patients setting, which needs further randomized studies. Clinical trial information: NCT05087706.
- Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Zejula (niraparib) / GSK, J&J
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer. (Hall A; Poster Bd # 62) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2514;
P2
The combination of niraparib and HX008 demonstrated promising clinical benefits with a tolerable safety profile in MBC patients with germline BRCA1/2 mutations, even in patients with brain metastases. Clinical trial information: NCT04508803.
- TQB2930 / Sino Biopharm
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study. (Hall A; Poster Bd # 4) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2457;
P1/2
These early signs of activity support the further exploration of combination therapy of TQB2930 and the study is ongoing. Clinical trial information: NCT06202261.
- SPH5030 / Shanghai Pharma
Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors. (Hall A; Poster Bd # 262) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2089;
P1
A dose of 600 mg QD regimen could be considered for further clinical trials. Clinical trial information: NCT05245058.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): Primary analysis of a prospective, multicenter, response-adapted study. (Hall A; Poster Bd # 195) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1331;
P2
Further studies are warranted to identify biomarkers predicting those who may benefit from pyrotinib in addition to trastuzumab. Clinical trial information: NCT03847818.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Patient-derived tumor cell clusters (PTC) guiding-neoadjuvant therapy of HER2-positive breast cancer: A prospective randomized phase II clinical trial. (Hall A; Poster Bd # 173) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1309;
P2
1. Yin et al.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer. (Pubmed Central) - Apr 24, 2024
Importantly, this multimodal therapy also promotes the upregulation of genes related to TNF and NF-?B signaling pathways, enhancing immune activation and immunogenic cell death. In vivo studies confirm a significant reduction in tumor volume after treatment, substantiating the potential effectiveness of these nanocarriers.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Review: Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses. (Pubmed Central) - Apr 18, 2024
Based on these findings, trastuzumab-containing regimens emerge as a preferable and recommended choice in clinical practice for managing HER2-positive breast cancer. PROSPERO, identifier CRD42023414348.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Journal: Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer. (Pubmed Central) - Apr 15, 2024
In summary, our research reveals the molecular mechanisms of irreversible HER2-TKIs in regulating HER2 protein expression by promoting HER2 internalization. These findings advance our comprehension of targeted therapy for GC and provide a promising therapeutic combination strategy with enhanced efficacy against HER2-positive GC.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 12, 2024
P2, N=72, Not yet recruiting, Sponsor: Huihua Xiong
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
P2 data, Journal: Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial. (Pubmed Central) - Apr 11, 2024
These findings advance our comprehension of targeted therapy for GC and provide a promising therapeutic combination strategy with enhanced efficacy against HER2-positive GC. In this single-arm exploratory phase II trial, patients with treatment-na
- | Zynyz (retifanlimab-dlwr) / Incyte, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date, Oncolytic virus, IO biomarker, Metastases: NCI-2020-02940: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (clinicaltrials.gov) - Apr 4, 2024
P2, N=25, Recruiting, Sponsor: Mridula George, MD
In this single-arm exploratory phase II trial, patients with treatment-na Trial primary completion date: Jan 2024 --> Jun 2024
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal, Metastases: Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer. (Pubmed Central) - Apr 1, 2024
In the first-, second- and third-line treatment, pyrotinib plus trastuzumab and chemotherapy is effective and safe. Pyrotinib and trastuzumab combined with Albumin-bound paclitaxel may be a potential ideal treatment plan for HER2-positive advanced breast cancer.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal, Combination therapy: Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases. (Pubmed Central) - Apr 1, 2024
Importantly, the QoL was efficiently maintained throughout the treatment duration. Pyrotinib and capecitabine combination therapy proved significant effectiveness as well as tolerability in treating HER2-positive BC with BMs, yielding satisfactory results, especially in radiotherapy-naive population.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients. (Pubmed Central) - Mar 25, 2024
The common adverse events included diarrhea (84.2%), anemia (73.7%), nausea and vomiting (63.2%), fatigue (50.0%), hypomagnesemia (44.7%), leukopenia (42.1%), thrombocytopenia (39.5%), elevated transaminase (36.8%), and pruritus (31.6%). Pyrotinib and trastuzumab plus chemotherapy serve as an acceptable neoadjuvant regimen exhibiting good efficacy and tolerance in HER2+ breast cancer patients, while further large-scale validation is warranted.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal, Metastases: A comprehensive clinical evaluation of HER2-TKIs in patients with previously treated HER2-positive metastatic breast cancer. (Pubmed Central) - Mar 22, 2024
Pyrotinib is more valuable in clinics with better safety, effectiveness, economy, suitability, accessibility, and innovation in HER2-positive MBC. This study could provide references for the clinical application of HER2-TKIs in treating HER2-positive MBC.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open: Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer (clinicaltrials.gov) - Mar 22, 2024
P2, N=1008, Recruiting, Sponsor: Fudan University
This study could provide references for the clinical application of HER2-TKIs in treating HER2-positive MBC. Not yet recruiting --> Recruiting
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Three-year invasive disease-free survival results from a phase 2 study of pyrotinib plus trastuzumab and albumin-bound paclitaxel as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_372;
P1/2
After surgery, patients were scheduled to be given 4 cycles of adjuvant anthracycline plus cyclophosphamide, followed by HER2-targeted therapy at the physician's discretion, adjuvant irradiation, and endocrine therapy, if applicable... Compared to the dual-HER2 blockades, adding pyrotinib to the combo regimen of chemotherapy and trastuzumab further improved the pCR rate which consequently translates to the iDFS benefit in non-metastatic BC, justifying the rationality of synergizing small molecule tyrosine kinase inhibitors, trastuzumab, and chemotherapy.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Neoadjuvant pyrotinib combined with trastuzumab, albumin paclitaxel, and carboplatin for HER2-positive early or locally advanced breast cancer: a single-arm phase II trial (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_370;
Neoadjuvant pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin is an effective and safe treatment option for HER2-positive early or locally advanced breast cancer. The randomized controlled trial is necessary to validate our findings.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Clinical, Retrospective data, Review, Journal: Safety and efficacy of pyrotinib for HER?2?positive breast cancer in the neoadjuvant setting: A systematic review and meta?analysis. (Pubmed Central) - Mar 18, 2024
The management of adverse events should be paid great attention to, during pyrotinib therapy, although pyrotinib-contained neoadjuvant therapy could be an effective treatment for patients with early-stage or locally advanced HER2-positive breast cancer. Head-to-head randomized clinical trials are warranted to further confirm the benefits and risks associated with pyrotinib therapy in patients with breast cancer.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer. (Pubmed Central) - Mar 12, 2024
P2
This four-drug neoadjuvant regimen shows promising pathological response with an acceptable safety profile in patients with TPBC. A randomized controlled trial (NCT05638594) of this regimen is being conducted.
- |||| JS105 / Shanghai Junshi Biosci, Risen (Suzhou) Biosci
Enrollment open, Combination therapy, Metastases: A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors (clinicaltrials.gov) - Mar 12, 2024
P1/2, N=306, Recruiting, Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.
A randomized controlled trial (NCT05638594) of this regimen is being conducted. Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Retrospective data, Journal, Real-world evidence, Real-world: Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study. (Pubmed Central) - Mar 8, 2024
RC48 exhibited potent activity for patients regardless of trastuzumab resistance or refractory. The sequence of pyrotinib and RC48 did not influence their total efficacy, indicating no cross-resistance.
- Clinical efficacy and safety of HER2 targeted therapy in patients with metastatic colorectal cancer: A systematic review and meta-analysis (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_5145;
Systematic review identified 9 study cohorts which were utilized in the meta-analysis, encompassing a total of 279 patients with mCRC who received Trastuzumab (T) in combination with either Pertuzumab (P), Tucatinib (Tu), Pyrotinib (Py), or Lapatinib (L). Overall, this comprehensive meta-analysis confirms that dual HER2 targeting therapies yield meaningful clinical efficacy, with favorable safety profiles, and improve outcomes in patients with RAS-WT HER2-positive mCRC.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Enrollment open: Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer (clinicaltrials.gov) - Feb 28, 2024
P=N/A, N=30, Recruiting, Sponsor: Youzhi Zhu
Overall, this comprehensive meta-analysis confirms that dual HER2 targeting therapies yield meaningful clinical efficacy, with favorable safety profiles, and improve outcomes in patients with RAS-WT HER2-positive mCRC. Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal, Combination therapy, Metastases: Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option? (Pubmed Central) - Feb 26, 2024
Not yet recruiting --> Recruiting No abstract available
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Metastases: YOUNGBC-21: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab (clinicaltrials.gov) - Feb 26, 2024
P=N/A, N=333, Completed, Sponsor: Fudan University
No abstract available Active, not recruiting --> Completed | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Sep 2023
- ||| GQ1001 / GeneQuantum Healthcare, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open, Trial completion date, Trial primary completion date, Metastases: GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 25, 2024
P1/2, N=75, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Completed | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Sep 2023 Active, not recruiting --> Recruiting | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date, Metastases: A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases (clinicaltrials.gov) - Feb 15, 2024
P2, N=362, Recruiting, Sponsor: Jiangxi Provincial Cancer Hospital
Active, not recruiting --> Recruiting | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025 Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2025